Search Results

Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, is pleased to announce that a complete response patient (CR) in Glioblastoma (GBM) cohort from first in human study VT1021-01 (NCT03364400) has now completed 3 full years of dosing with VT1021.

Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, announced encouraging new data from its phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma.

Vigeo Therapeutics today announced new data from its Phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma (rGBM).

Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vigeo Therapeutics -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven’s troriluzole and Vigeo’s VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).

Vigeo Therapeutics today announced new clinical data from its Phase 1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with recurrent glioblastoma (rGBM).

Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, announced completion of the Phase 1/2 dose expansion studies evaluating its lead asset VT1021 in recurrent glioblastoma and pancreatic cancer.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new clinical data from its Phase 1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with pancreatic cancer and recurrent glioblastoma (rGBM).

Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced it will have two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 2021 Annual Meeting, taking place from November 10-14, 2021.

VT1021 Selected by Global Coalition for Adaptive Research (GCAR) for Inclusion in Its GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients with Glioblastoma.